Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
(1) Three cholinesterase inhibitors are marketed in France for the treatment of Alzheimer's disease: donepezil, galantamine and rivastigmine. Tremor and dystonia are known adverse effects of cholinesterase inhibitors. (2) In patients with Parkinson's disease who have cognitive disorders, or in patients with Lewy body dementia, exacerbations of parkinsonism and tremor have been observed during treatment with cholinesterase inhibitors at normal doses. The disorders were reversible on withdrawal of the cholinesterase inhibitor. (3) Withdrawal of cholinesterase inhibitors should be considered if gait disorders, falls or parkinsonism occur or worsen during treatment.
D000544:Alzheimer Disease / Q000188:drug therapy; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003704:Dementia / Q000150:complications / Q000188:drug therapy; D004421:Dystonia / Q000139:chemically induced*; D005602:France; D005702:Galantamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D020961:Lewy Body Disease / Q000150:complications / Q000188:drug therapy; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy; D048448:Phenylcarbamates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014202:Tremor / Q000139:chemically induced*
D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine